Eli Lilly: encouraging data in atopic dermatitis
(CercleFinance.com) - Eli Lilly reports that patients with moderate-to-severe atopic dermatitis treated with the investigational lebrikizumab for up to two years experienced sustained skin clearance, relief of itching and reduction in disease severity with monthly maintenance dosing, as demonstrated in the long-term extension study "ADjoin".
The results of the study will be presented at the 43rd Annual Autumn Conference on Clinical Dermatology, to be held in Las Vegas from 19 to 22 October.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The results of the study will be presented at the 43rd Annual Autumn Conference on Clinical Dermatology, to be held in Las Vegas from 19 to 22 October.
Copyright (c) 2023 CercleFinance.com. All rights reserved.